Brian Lestini, Pyramid Biosciences CEO

Pyra­mid inks TROP2 pact with Chi­na biotech to fol­low suit of Gilead, As­traZeneca-Dai­ichi Sankyo

Look­ing to go where Gilead al­ready is and where As­traZeneca-part­nered Dai­ichi Sankyo is head­ed, Pyra­mid Bio­sciences has locked in a pact for a TROP2-tar­get­ed an­ti­body-drug con­ju­gate.

The Bridge­wa­ter, NJ biotech is link­ing up with Chi­na-based GeneQuan­tum Health­care to gain ac­cess to GQ1010, which will en­ter a glob­al clin­i­cal tri­al with­in 12 months, the com­pa­nies said Thurs­day.

The deal marks an ex­pand­ed fo­cus in on­col­o­gy for Pyra­mid, where it al­ready has a Phase I for an­oth­er as­set, and as it looks to part­ner out a Phase II-ready der­ma­tol­ogy drug can­di­date with a bio­phar­ma in that space, CEO Bri­an Les­ti­ni told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.